Lattice Incorporated

Lattice Incorporated specializes in blood bank information system application software. These systems are designed to streamline and automate the management of blood bank operations, including inventory tracking and workflow coordination. Since these are software-based solutions, they fall under the broader category of digital health tools tailored for clinical environments.

Lattice Incorporated is based in the United States. While the company’s location influences its regulatory framework, it does not inherently determine whether its devices are approved or cleared—only individual products undergo authorization processes. The company’s devices are regulated under U.S. medical device laws, which classify them based on risk and intended use.

Lattice Incorporated’s devices are classified as Class II medical devices. This classification is determined by the FDA based on the level of risk associated with the device’s intended use. Class II devices generally pose moderate risk and require special controls beyond general controls to ensure safety and effectiveness, such as performance standards or post-market surveillance.

Yes, Lattice Incorporated’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This registry assigns a standardized identifier to each device, improving traceability, reducing medical errors, and facilitating post-market surveillance. Listing in the UDI database is a requirement for many Class II devices in the U.S., ensuring transparency and compliance with regulatory tracking systems.

An example of Lattice Incorporated’s product is MediCopia, a blood bank information system application software. This software is designed to automate and integrate key functions within blood banks, such as inventory management, donor tracking, and compliance reporting. By digitizing workflows, MediCopia helps reduce human error, improve efficiency, and ensure adherence to regulatory standards for blood safety and handling.